dihydroxyphenylalanine has been researched along with Endocrine Gland Neoplasms in 5 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In detecting pheochromocytoma (PHEO), positron emission tomography (PET) with the radiolabelled amine precursor (18)F-fluorodihydroxyphenylalanine ((18)F-DOPA) offers excellent specificity, while computed tomography (CT) provides high sensitivity and ability to localize lesions; therefore, the combination of these modalities could be advantageous in this setting." | 7.76 | Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. ( Buck, AK; Dralle, H; Glatting, G; Karges, W; Luster, M; Mottaghy, FM; Neumaier, B; Pauls, S; Reske, SN; Solbach, C; Verburg, FA; Zeich, K, 2010) |
| "In detecting pheochromocytoma (PHEO), positron emission tomography (PET) with the radiolabelled amine precursor (18)F-fluorodihydroxyphenylalanine ((18)F-DOPA) offers excellent specificity, while computed tomography (CT) provides high sensitivity and ability to localize lesions; therefore, the combination of these modalities could be advantageous in this setting." | 3.76 | Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. ( Buck, AK; Dralle, H; Glatting, G; Karges, W; Luster, M; Mottaghy, FM; Neumaier, B; Pauls, S; Reske, SN; Solbach, C; Verburg, FA; Zeich, K, 2010) |
| "Seventy-seven consecutive carcinoid patients who underwent an 18F-dopa PET scan in two previously published studies were analysed." | 1.37 | Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. ( Brouwers, AH; de Jong, JR; de Vries, EG; Dierckx, RA; Fiebrich, HB; Kema, IP; Koopmans, KP; Links, TP; Sluiter, W; Walenkamp, AM, 2011) |
| "The greatest impact was observed for carcinoid tumors (50%: 11 of 22) and was clinically relevant in every case, followed by occult endocrine tumors (16%: four of 25), and was clinically relevant in three of the four cases, and noncarcinoid tumors (13%: 3 of 22), clinically relevant in only one case." | 1.35 | Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. ( Bouchard, P; Duron, F; Grangé, JD; Houry, S; Huchet, V; Kerrou, K; Lotz, JP; Montravers, F; Nataf, V; Rougier, P; Ruszniewski, P; Talbot, JN, 2009) |
| "Conversely, in noncarcinoid tumors, the extent of the disease was more accurately evaluated in all cases by (111)In-pentetreotide SRS than by (18)F-FDOPA PET." | 1.33 | Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? ( Aide, N; de Beco, V; Grahek, D; Grangé, JD; Gutman, F; Kerrou, K; Lotz, JP; Montravers, F; Ruszniewski, P; Talbot, JN, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montravers, F | 2 |
| Kerrou, K | 2 |
| Nataf, V | 1 |
| Huchet, V | 1 |
| Lotz, JP | 2 |
| Ruszniewski, P | 2 |
| Rougier, P | 1 |
| Duron, F | 1 |
| Bouchard, P | 1 |
| Grangé, JD | 2 |
| Houry, S | 1 |
| Talbot, JN | 2 |
| Luster, M | 1 |
| Karges, W | 1 |
| Zeich, K | 1 |
| Pauls, S | 1 |
| Verburg, FA | 1 |
| Dralle, H | 1 |
| Glatting, G | 1 |
| Buck, AK | 1 |
| Solbach, C | 1 |
| Neumaier, B | 1 |
| Reske, SN | 1 |
| Mottaghy, FM | 1 |
| Dudczak, R | 1 |
| Traub-Weidinger, T | 1 |
| Fiebrich, HB | 1 |
| de Jong, JR | 1 |
| Kema, IP | 1 |
| Koopmans, KP | 1 |
| Sluiter, W | 1 |
| Dierckx, RA | 1 |
| Walenkamp, AM | 1 |
| Links, TP | 1 |
| Brouwers, AH | 1 |
| de Vries, EG | 1 |
| Grahek, D | 1 |
| de Beco, V | 1 |
| Aide, N | 1 |
| Gutman, F | 1 |
1 review available for dihydroxyphenylalanine and Endocrine Gland Neoplasms
| Article | Year |
|---|---|
PET and PET/CT in endocrine tumours.
Topics: Carbon Radioisotopes; Dihydroxyphenylalanine; Endocrine Gland Neoplasms; Fluorodeoxyglucose F18; Gal | 2010 |
4 other studies available for dihydroxyphenylalanine and Endocrine Gland Neoplasms
| Article | Year |
|---|---|
Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors.
Topics: Adult; Biopsy; Carcinoid Tumor; Dihydroxyphenylalanine; Endocrine Gland Neoplasms; Fluorodeoxyglucos | 2009 |
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
Topics: Adolescent; Adult; Aged; Biological Transport; Child; Dihydroxyphenylalanine; Endocrine Gland Neopla | 2010 |
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour.
Topics: Adolescent; Adult; Aged; Biological Transport; Carcinoid Tumor; Dihydroxyphenylalanine; Endocrine Gl | 2011 |
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Topics: Adult; Aged; Carcinoid Tumor; Digestive System Neoplasms; Dihydroxyphenylalanine; Endocrine Gland Ne | 2006 |